RIPOR1 (Gene)

Synonyms:ENTREZ:79567, FAM65A, HGNC:25836, NM_001193522, NM_001193523, NM_001193524, NM_024519, NP_001180451, NP_001180452, NP_001180453, NP_078795, RHO family interacting cell polarization regulator 1, RIPOR1, XM_011523321, XM_011523322, XM_011523324, XM_011523325, XM_011523326, XM_017023663, XM_017023664, XM_024450442, XM_024450443, XP_011521623, XP_011521624, XP_011521626, XP_011521627, XP_011521628, XP_016879152, XP_016879153, XP_024306210, XP_024306211
Omim:OMIM:619842
Id:61998c22-eacb-59c7-9452-4e3b84e269a2
Hgnc:HGNC:25836
Entrez:79567
Description:RHO family interacting cell polarization regulator 1
Enables 14-3-3 protein binding activity. Involved in several processes, including establishment of Golgi localization; negative regulation of Rho guanyl-nucleotide exchange factor activity; and negative regulation of Rho protein signal transduction. Located in Golgi apparatus; cell leading edge; and membrane. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View RIPOR1's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with RIPOR1.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using RIPOR1.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for RIPOR1.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with RIPOR1.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.